Sandro Pignata, MD, PhD, on Ovarian and Related Gynecologic Cancers: Expert Perspective on Three Key Trials
2017 ESMO CongressSandro Pignata, MD, PhD, of the Istituto Nazionale dei Tumori, summarizes findings from the ICON8 study on dose-dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma treatment; the ARIEL3 study on rucaparib vs placebo in recurrent ovarian carcinoma; and the ENGOT-OV16/NOVA on quality of life in patients with recurrent ovarian cancer treated with niraparib (Abstracts 929O, LBA40, 930O).
Related Videos
Mansoor Mirza, MD: Ovarian Cancer Treatment and Quality of Life
Mansoor Mirza, MD, of Copenhagen University Hospital, discusses quality of life in patients with recurrent ovarian cancer treated with niraparib (Abstract 930O).
Jeffrey S. Weber, MD, PhD, on Melanoma: Results of the CheckMate 238 Trial
Jeffrey S. Weber, MD, PhD, of New York University’s Langone Medical Center, discusses study results on adjuvant therapy with nivolumab vs ipilimumab after complete resection of sta...
Luis G. Paz-Ares, MD, PhD, on NSCLC: Results of the PACIFIC Trial
Luis G. Paz-Ares, MD, PhD, of Hospital Universitario 12 De Octubre, discusses phase III study findings on durvalumab after chemoradiation therapy in patients with stage III, locall...
Sibylle Loibl, MD, PhD, on Metastatic Breast Cancer: Expert Perspective on CDK4 Inhibitors
Sibylle Loibl, MD, PhD, of the German Breast Group, summarizes a session she chaired in which the rationale to target CDK4, data on efficacy of the inhibitors, and triple combinati...
Andrew R. Clamp, PhD, on Gynecologic Cancers: Results of the ICON8 Trial
Andrew R. Clamp, PhD, of The Christie NHS Foundation Trust, discusses his phase III study findings on dose-dense chemotherapy integration in first-line treatment of epithelial ovar...
